Gene Editing Market Predicted to Accelerate the Growth by 2019 – 2025Posted by Shristi on October 15th, 2019 Analyst Speak: “The Global Genome Editing Market was valued around US$ 4.2 Bn by 2018 and growing at a significant CAGR of 13.6% over next seven years 2019-2025 due to high occurrence of infectious diseases and cancer” The global genome editing market accounted for US$ 4.2 Bn in 2018 and burgeoning over the forthcoming years. High occurrence of infectious diseases and cancer, increase in funding for genetic research in developed economies, rising government funding and growth in the number of genomics projects, technological improvements in the biotechnology sector and use of genome editing in specialized/personalized medicine are some key factors influencing the market growth. However, factors such as adverse public perception of genetic research and high cost of genomic equipment are the major factors hindering the market growth. In addition, high growth in emerging economies provides huge growth opportunity for the market. Global genome editing market segmented on the basis of product, technology, application, end user and region. Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=16100 Zinc Finger Nuclease (ZFN) dominate the Global Genome Editing Market Based on technology, global genome editing market is segmented zinc finger nuclease (ZFN), clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN) and others. Zinc-finger nucleases held considerable market share. Zinc-finger nucleases are synthetic restriction enzymes produced by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. They can be engineered to target specific preferred DNA sequences and this allows zinc-finger nucleases to target exclusive sequences within complex genomes. Asia Pacific Leads the Global Genome Editing market PBI’s global genome editing market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. Asia Pacific accounted larger revenue share in global genome editing market with considerable CAGR. The growth in this region is due to increasing number of laboratories, huge spending on R & D and expansion of leading genome editing companies. Also, India is the major contributor for the growth of the market in this region. In addition, North America held significant market share during estimated period owing to growing focus on the development of gene therapies in the US. Strategic Approvals are the Key Strategies Adopted by Market Players Global genome editing market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, In July 2017 Sangamo Therapeutics, Inc. received the U.S.FDA Fast Track designation for in vivo genome editing product candidates SB-318 and SB-913 to treat Mucopolysaccharidosis Type I (MPS I) and MPS II. Key player’s profiles in the report are Cellectis S.A. (France), Applied Stemcell, Inc. (U.S.), Genscript (U.S.), Merck KGaA (Germany), Horizon Discovery Group plc(U.K.), Origene Technologies, Inc. (U.S.), System Biosciences, Inc. (U.S.), Sangamo Therapeutics, Inc.(U.S.), Thermo Fisher Scientific (U.S) and Transposagen Biopharmaceuticals, Inc.(U.S.). For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-gene-editing-market/ Detailed Segmentation By Product
By Technology
By Application
By End User
By Geography North America
Europe
Asia-Pacific
Latin America
Middle East and Africa (MEA)
About Us: Like it? Share it! More by this author |